Phase I Trial of Dose-Escalated Whole Liver Irradiation with Hepatic Arterial Fluorodeoxyuridine/Leucovorin and Streptozotocin Followed by Fluorodeoxyuridine/Leucovorin and Chemoembolization for Patients with Neuroendocrine Hepatic Metastases

摘要

ObjectivesWe have previously shown that refractory neuroendocrine tumors can respond to moderate doses of chemoradiotherapy. We completed a dose-escalation phase I/II trial combining hepatic arterial (HA) chemotherapy, chemoembolization, and dose-escalated whole liver radiotherapy (WLRT) to determine the maximum safe dose of radiation that could be delivered and to make a preliminary assessment of response.